[Federal Register: February 13, 2009 (Volume 74, Number 29)]
[Proposed Rules]
[Page 7194-7196]
[DOCID:fr13fe09-9]

========================================================================
Proposed Rules
                                                Federal Register
________________________________________________________________________

This section of the FEDERAL REGISTER contains notices to the public of
the proposed issuance of rules and regulations. The purpose of these
notices is to give interested persons an opportunity to participate in
the rule making prior to the adoption of the final rules.

========================================================================

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2009-0124; Directorate Identifier 2009-CE-004-AD]
RIN 2120-AA64

Airworthiness Directives; EADS SOCATA Model TBM 700 Airplanes

AGENCY: Federal Aviation Administration (FAA), Department of
Transportation (DOT).

ACTION: Notice of proposed rulemaking (NPRM).

-----------------------------------------------------------------------

SUMMARY: We propose to adopt a new airworthiness directive (AD) for the
products listed above. This proposed AD results from mandatory
continuing airworthiness information (MCAI) originated by an aviation
authority of another country to identify and correct an unsafe
condition on an aviation product. The MCAI describes the unsafe
condition as:

    A damaged wiring harness which caused the air conditioning
system circuit breaker to trip and evidencing a local overheating
has been found on an in-service aircraft.
    The investigation revealed that the damage (chafed wires) found
on the wiring harness resulted from an interference with the under-
floor attachment fittings of the cabin partition net which was due
to an incorrect routing of the harness while on the production line.
    Such conditions could result in an electrical short and
potential loss of several functions essential for the safety of
flight.

The proposed AD would require actions that are intended to address the
unsafe condition described in the MCAI.

DATES: We must receive comments on this proposed AD by March 16, 2009.

ADDRESSES: You may send comments by any of the following methods:
     Federal eRulemaking Portal: Go to http://
www.regulations.gov. Follow the instructions for submitting comments.
     Fax:<PHONE_NUMBER>.
     Mail: U.S. Department of Transportation, Docket
Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue, SE., Washington, DC 20590.
     Hand Delivery: U.S. Department of Transportation, Docket
Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue, SE., Washington, DC 20590, between 9 a.m. and 5 p.m.,
Monday through Friday, except Federal holidays.

Examining the AD Docket

    You may examine the AD docket on the Internet at http://
www.regulations.gov; or in person at the Docket Management Facility
between 9 a.m. and 5 p.m., Monday through Friday, except Federal
holidays. The AD docket contains this proposed AD, the regulatory
evaluation, any comments received, and other information. The street
address for the Docket Office (telephone<PHONE_NUMBER>) is in the
ADDRESSES section. Comments will be available in the AD docket shortly
after receipt.

FOR FURTHER INFORMATION CONTACT: Albert Mercado, Aerospace Engineer,
FAA, Small Airplane Directorate, 901 Locust, Room 301, Kansas City,
Missouri 64106; telephone:<PHONE_NUMBER>; fax:<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

Comments Invited

    We invite you to send any written relevant data, views, or
arguments about this proposed AD. Send your comments to an address
listed under the ADDRESSES section. Include ``Docket No. FAA-2009-0124;
Directorate Identifier 2009-CE-004-AD'' at the beginning of your
comments. We specifically invite comments on the overall regulatory,
economic, environmental, and energy aspects of this proposed AD. We
will consider all comments received by the closing date and may amend
this proposed AD because of those comments.
    We will post all comments we receive, without change, to http://
www.regulations.gov, including any personal information you provide. We
will also post a report summarizing each substantive verbal contact we
receive about this proposed AD.

Discussion

    The European Aviation Safety Agency (EASA), which is the Technical
Agent for the Member States of the European Community, has issued EASA
AD No.: 2009-0006, dated January 13, 2009 (referred to after this as
``the MCAI''), to correct an unsafe condition for the specified
products. The MCAI states:

    A damaged wiring harness which caused the air conditioning
system circuit breaker to trip and evidencing a local overheating
has been found on an in-service aircraft.
    The investigation revealed that the damage (chafed wires) found
on the wiring harness resulted from an interference with the under-
floor attachment fittings of the cabin partition net which was due
to an incorrect routing of the harness while on the production line.
    Such conditions could result in an electrical short and
potential loss of several functions essential for the safety of
flight.
    For the reason stated above, this AD mandates inspection of the
electrical wiring harness, and if necessary a rework of its routing.

You may obtain further information by examining the MCAI in the AD
docket.

Relevant Service Information

    EADS SOCATA has issued Mandatory Service Bulletin SB 70-163, dated
November 2008. The actions described in this service information are
intended to correct the unsafe condition identified in the MCAI.

FAA's Determination and Requirements of the Proposed AD

    This product has been approved by the aviation authority of another
country, and is approved for operation in the United States. Pursuant
to our bilateral agreement with this State of Design Authority, they
have notified us of the unsafe condition described in the MCAI and
service information referenced above. We are proposing this AD because
we evaluated all information and determined the unsafe condition exists
and is likely to exist or develop on other products of the same type
design.

Differences Between This Proposed AD and the MCAI or Service
Information

    We have reviewed the MCAI and related service information and, in
general, agree with their substance. But we might have found it
necessary to use different words from those in the MCAI to ensure the
AD is clear for U.S. operators and is enforceable. In making these
changes, we do not intend to differ substantively from the information
provided in the MCAI and related service information.

    We might also have proposed different actions in this AD from those
in the MCAI in order to follow FAA policies. Any such differences are
highlighted in a NOTE within the proposed AD.

Costs of Compliance

    We estimate that this proposed AD will affect 45 products of U.S.
registry. We also estimate that it would take about 1 work-hour per
product to comply with the basic requirements of this proposed AD. The
average labor rate is $80 per work-hour. Where the service information
lists required labor that is covered under warranty, we have assumed
that there will be no charge for this labor. As we do not control
warranty coverage for affected parties, some parties may incur costs
higher than estimated here.
    Based on these figures, we estimate the cost of the proposed AD on
U.S. operators to be $3,600, or $80 per product.
    In addition, we estimate that any necessary follow-on actions would
take about 1.5 work-hours, for a cost of $120 per product. We have no
way of determining the number of products that may need these actions.

Authority for This Rulemaking

    Title 49 of the United States Code specifies the FAA's authority to
issue rules on aviation safety. Subtitle I, section 106, describes the
authority of the FAA Administrator. ``Subtitle VII: Aviation
Programs,'' describes in more detail the scope of the Agency's
authority.
    We are issuing this rulemaking under the authority described in
``Subtitle VII, Part A, Subpart III, Section 44701: General
requirements.'' Under that section, Congress charges the FAA with
promoting safe flight of civil aircraft in air commerce by prescribing
regulations for practices, methods, and procedures the Administrator
finds necessary for safety in air commerce. This regulation is within
the scope of that authority because it addresses an unsafe condition
that is likely to exist or develop on products identified in this
rulemaking action.

Regulatory Findings

    We determined that this proposed AD would not have federalism
implications under Executive Order 13132. This proposed AD would not
have a substantial direct effect on the States, on the relationship
between the national Government and the States, or on the distribution
of power and responsibilities among the various levels of government.
    For the reasons discussed above, I certify this proposed
regulation:
    1. Is not a ``significant regulatory action'' under Executive Order
12866;
    2. Is not a ``significant rule'' under the DOT Regulatory Policies
and Procedures (44 FR 11034, February 26, 1979); and
    3. Will not have a significant economic impact, positive or
negative, on a substantial number of small entities under the criteria
of the Regulatory Flexibility Act.
    We prepared a regulatory evaluation of the estimated costs to
comply with this proposed AD and placed it in the AD docket.

List of Subjects in 14 CFR Part 39

    Air transportation, Aircraft, Aviation safety, Incorporation by
reference, Safety.

The Proposed Amendment

    Accordingly, under the authority delegated to me by the
Administrator, the FAA proposes to amend 14 CFR part 39 as follows:

PART 39--AIRWORTHINESS DIRECTIVES

    1. The authority citation for part 39 continues to read as follows:

    Authority: 49 U.S.C. 106(g), 40113, 44701.

Sec.  39.13  [Amended]

    2. The FAA amends Sec.  39.13 by adding the following new AD:

EADS SOCATA: Docket No. FAA-2009-0124; Directorate Identifier 2009-
CE-004-AD.

Comments Due Date

    (a) We must receive comments by March 16, 2009.

Affected ADs

    (b) None.

Applicability

    (c) This AD applies to TBM 700 airplanes, serial numbers 434
through 478, certificated in any category.

Subject

    (d) Air Transport Association of America (ATA) Code 92: Wiring
Elements.

Reason

    (e) The mandatory continuing airworthiness information (MCAI)
states:

    A damaged wiring harness which caused the air conditioning
system circuit breaker to trip and evidencing a local overheating
has been found on an in-service aircraft.
    The investigation revealed that the damage (chafed wires) found
on the wiring harness resulted from an interference with the under-
floor attachment fittings of the cabin partition net which was due
to an incorrect routing of the harness while on the production line.
    Such conditions could result in an electrical short and
potential loss of several functions essential for the safety of
flight.
    For the reason stated above, this AD mandates inspection of the
electrical wiring harness, and if necessary a rework of its routing.

Actions and Compliance

    (f) Unless already done, do the following actions:
    (1) Within the next 100 hours time-in-service after the
effective date of this AD or within the next 12 months after the
effective date of this AD, whichever occurs first, inspect the
electrical wiring harness at frame C14 and between frames C16 and
C17 for wire chafing and incorrect routing following EADS SOCATA
Service Bulletin SB 70-163, dated November 2008.
    (2) If any wire chafing and/or incorrect routing are found,
before further flight, repair and reroute the electrical harness
following EADS SOCATA Service Bulletin SB 70-163, dated November
2008.

FAA AD Differences

    Note: This AD differs from the MCAI and/or service information
as follows: No differences.

Other FAA AD Provisions

    (g) The following provisions also apply to this AD:
    (1) Alternative Methods of Compliance (AMOCs): The Manager,
Standards Office, FAA, has the authority to approve AMOCs for this
AD, if requested using the procedures found in 14 CFR 39.19. Send
information to ATTN: Albert Mercado, Aerospace Engineer, FAA, Small
Airplane Directorate, 901 Locust, Room 301, Kansas City, Missouri
64106; telephone:<PHONE_NUMBER>; fax:<PHONE_NUMBER>. Before using
any approved AMOC on any airplane to which the AMOC applies, notify
your appropriate principal inspector (PI) in the FAA Flight
Standards District Office (FSDO), or lacking a PI, your local FSDO.
    (2) Airworthy Product: For any requirement in this AD to obtain
corrective actions from a manufacturer or other source, use these
actions if they are FAA-approved. Corrective actions are considered
FAA-approved if they are approved by the State of Design Authority
(or their delegated agent). You are required to assure the product
is airworthy before it is returned to service.
    (3) Reporting Requirements: For any reporting requirement in
this AD, under the provisions of the Paperwork Reduction Act (44
U.S.C. 3501 et seq.), the Office of Management and Budget (OMB) has
approved the information collection requirements and has assigned
OMB Control Number 2120-0056.

Related Information

    (h) Refer to MCAI European Aviation Safety Agency (EASA) AD No.:
2009-0006, dated January 13, 2009; and EADS SOCATA Service Bulletin
SB 70-163, dated November 2008, for related information.

    Issued in Kansas City, Missouri, on February 6, 2009.
Kim Smith,
Manager, Small Airplane Directorate, Aircraft Certification Service.
 [FR Doc. E9-3104 Filed 2-12-09; 8:45 am]

BILLING CODE 4910-13-P


[Federal Register Volume 88, Number 196 (Thursday, October 12, 2023)]
[Notices]
[Pages 70669-70672]
[FR Doc No: 2023-22586]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2023-N-3768]

Agency Information Collection Activities; Proposed Collection;
Comment Request; Adherence Potential and Patient Preference in
Prescription Drug Promotion

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is
announcing an opportunity for public comment on the proposed collection
of certain information by the Agency. Under the Paperwork Reduction Act
of 1995 (PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information and
to allow 60 days for public comment in response to the notice. This
notice solicits comments on a proposed study entitled ``Adherence
Potential and Patient Preference in Prescription Drug Promotion.''

DATES: Either electronic or written comments on the collection of
information must be submitted by December 11, 2023.

ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. The https://www.regulations.gov electronic filing system will accept comments until
11:59 p.m. Eastern Time at the end of December 11, 2023. Comments
received by mail/hand delivery/courier (for written/paper submissions)
will be considered timely if they are received on or before that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as

well as any attachments, except for information submitted, marked and
identified, as confidential, if submitted as detailed in
``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2023-N-3768 for ``Agency Information Collection Activities;
Proposed Collection; Comment Request; Adherence Potential and Patient
Preference in Prescription Drug Promotion.'' Received comments, those
filed in a timely manner (see ADDRESSES), will be placed in the docket
and, except for those submitted as ``Confidential Submissions,''
publicly viewable at https://www.regulations.gov or at the Dockets
Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-
402-7500.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852,<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: JonnaLynn Capezzuto, Office of
Operations, Food and Drug Administration, Three White Flint North, 10A-
12M, 11601 Landsdown St., North Bethesda, MD 20852,<PHONE_NUMBER>,
[email protected].

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3521), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information before
submitting the collection to OMB for approval. To comply with this
requirement, FDA is publishing notice of the proposed collection of
information set forth in this document.
    With respect to the following collection of information, FDA
invites comments on these topics: (1) whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.

Adherence Potential and Patient Preference in Prescription Drug
Promotion

OMB Control Number 0910--NEW

    Section 1701(a)(4) of the Public Health Service Act (42 U.S.C.
300u(a)(4)) authorizes FDA to conduct research relating to health
information. Section 1003(d)(2)(C) of the Federal Food, Drug, and
Cosmetic Act (FD&C Act) (21 U.S.C. 393(d)(2)(C)) authorizes FDA to
conduct research relating to drugs and other FDA-regulated products in
carrying out the provisions of the FD&C Act.
    The mission of the Office of Prescription Drug Promotion (OPDP) is
to protect the public health by helping to ensure that prescription
drug promotion is truthful, balanced, and accurately communicated so
that patients and healthcare providers can make informed decisions
about treatment options. OPDP's research program provides scientific
evidence to help ensure that our policies related to prescription drug
promotion will have the greatest benefit to public health. Toward that
end, we have consistently conducted research to evaluate the aspects of
prescription drug promotion that are most central to our mission,
focusing in particular on three main topic areas: advertising features,
including content and format; target populations; and research quality.
    Through the evaluation of advertising features, we assess how
elements such as graphics, format, and the characteristics of the
disease and product impact the communication and understanding of
prescription drug risks and benefits. Focusing on target populations
allows us to evaluate how understanding of prescription drug risks and
benefits may vary as a function of audience. Our focus on research
quality aims at maximizing the quality of research data through
analytical methodology development and investigation of sampling and
response issues. This study will inform the first topic area,
advertising features.
    Because we recognize that the strength of data and the confidence
in the robust nature of the findings are improved through the results
of multiple converging studies, we continue to develop evidence to
inform our thinking. We evaluate the results from our studies within
the broader context of research and findings from other sources, and
this larger body of knowledge collectively informs our policies as well
as our research program. Our research is documented on our home page at
https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/office-prescription-drug-promotion-opdp-research, which includes links
to the latest Federal Register notices and peer-reviewed publications
produced by our office.
    This study builds on OPDP's portfolio of research on market claims
and disclosures to explore the influence of statements around patient
adherence and preference in prescription drug promotion. Previous FDA-
funded research has shown that market claims that advertise drug
characteristics unrelated to medicinal properties, such as ``#1
Prescribed,'' influence consumer and provider perceptions about a
drug's efficacy (Ref. 1). In the same study, results of a tradeoff
analysis suggested that patients prefer a drug over a

competitor when this type of claim is present, and a drug without this
claim required at least 1.23 percent greater efficacy to be chosen over
a drug with this claim (Ref. 2). Treatment preferences may also be
influenced by other drug characteristics, including its impact on
quality of life, complexity of dosage regimens, administration mode,
and cost to family and self (Refs. 3-5).
    It is not known how claims that appeal to the possibility for
greater adherence or to social norms around what other patients or
healthcare providers prefer influence perceptions of a drug. A related
question is whether including a disclosure stating the uncertainty
around such claims (e.g., there is no conclusive research on whether
DRUG A results in better adherence) can mitigate any misleading
perceptions or influence preferences. Some evidence suggests that
disclosures in prescription drug promotion are typically noticed and
may help consumers and healthcare providers understand information
(Refs. 2 and 6), but this topic has not been investigated in the
context of adherence claims.
    The present research is designed to complement previous research by
experimentally examining the role of adherence and patient preference
claims in prescription drug promotion. We have the following specific
questions:
    Research questions:
    1. Does the presence or absence of an implied-adherence claim
affect consumers' behavioral intentions or risk, benefit, and adherence
perceptions?
    2. Does the presence or absence of an adherence-related patient
preference claim affect consumers' behavioral intentions or risk,
benefit, and adherence perceptions?
    3. Does the presence of both types of claims (adherence and
preference) have a cumulative impact on consumers' behavioral
intentions or risk, benefit, and adherence perceptions?
    4. Does a disclosure of information to the effect that there is no
conclusive research on whether the drug results in better adherence
mitigate consumers' behavioral intentions or risk, benefit, and
adherence perceptions?
    To complete this research, we will show participants a website for
a fictitious prescription drug product for type 2 diabetes. We propose
the design in table 1, which varies based on whether the fictitious
prescription drug promotional communication includes a claim about:
     implied adherence;
     patient preference; and
     a disclosure that there is no conclusive research on
adherence.

                               Table 1--Design 2 (Implied Adherence Claim) x 2 (Patient Preference Claim) x 2 (Disclosure)
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                With disclosure \1\                   Without disclosure
                                                                             ---------------------------------------------------------------------------
                                                                                Patient preference claim              Patient preference claim
                                                                             ---------------------------------------------------------------------------
                                                                                Yes                 No                Yes                 No
--------------------------------------------------------------------------------------------------------------------------------------------------------
Implied Adherence Claim........................  Yes.
                                                 No.
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ E.g., ``There is no conclusive research to suggest better adherence to Drug X compared with Drug Y.''

    Recruitment will occur by email through an internet panel, and
participant eligibility will be determined with a screener at the
beginning of the online survey. For the pretest, we expect to screen
253 consumers and 294 primary care physicians (PCPs) to reach our
desired number of completed surveys. We will conduct complete pretest
surveys with 160 consumers who self-identify as having been diagnosed
with diabetes and 160 PCPs who treat diabetes (both obtained from a
web-based research vendor) to ensure that the questionnaire programming
works as expected. For the main study, we expect to screen 566
consumers and 660 PCPs to reach our desired number of completed
surveys. Thus, for the main study final sample, we will recruit 360
adult voluntary participants aged 18 years or older who self-identify
as having been diagnosed with diabetes and 360 voluntary participants
who are employed as PCPs who treat diabetes. We will exclude
individuals who work in healthcare settings, employees of the
Department of Health and Human Services, and individuals who work in
the marketing, advertising, or pharmaceutical industries.
    The total annual estimated burden imposed by this collection of
information is 520 hours (table 2). These estimates account for over-
recruitment of 10 percent to account for survey incompletes. As with
most online and mail surveys, it is always possible that some
participants are in the process of completing the survey when the
target number is reached and that those surveys will be completed and
received before the survey is closed out. To account for this, we have
estimated approximately 10 percent overage.
    Each participant will see one of eight versions of a consumer web
page for a fictitious prescription diabetes treatment, as reflected in
table 1. They will answer a questionnaire designed to take no more than
20 minutes regarding benefit and risk perceptions, adherence
perceptions, behavioral intentions, adherence claim retention, and
patient preference claim retention. The survey is available upon
request at [email protected].

                                                     Table 2--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                   Number of
                   Activity                        Number of     responses per   Total annual        Average burden per response \2\        Total hours
                                                  respondents     respondent       responses
--------------------------------------------------------------------------------------------------------------------------------------------------------
Pretest:
    Consumers: pretest screener completes                  253               1             253  0.08 (5 min.)...........................              20
     (assumes 70% eligible).
    Consumers: number of completes, pretest...             176               1             176  0.33 (20 min.)..........................              58
    PCPs: pretest screener completes (assumes              294               1             294  0.08 (5 min.)...........................              24
     60% eligible).
    PCPs: number of completes, pretest........             176               1             176  0.33 (20 min.)..........................              58

Main Study:
    Consumers: number of main study screener               566               1             566  0.08 (5 min.)...........................              45
     completes (assumes 70% eligible).
    Consumers: number of completes, main study             396               1             396  0.33 (20 min.)..........................             131
    PCPs: number of main study screener                    660               1             660  0.08 (5 min.)...........................              53
     completes (assumes 60% eligible).
    PCPs: number of completes, main study.....             396               1             396  0.33 (20 min.)..........................             131
                                               ---------------------------------------------------------------------------------------------------------
        Total (rounded).......................  ..............  ..............  ..............  ........................................             520
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
\2\ Burden estimates of less than 1 hour are expressed as a fraction of an hour in decimal format.

References

    The following references are on display with the Dockets Management
Staff (see ADDRESSES) and are available for viewing by interested
persons between 9 a.m. and 4 p.m., Monday through Friday; these are not
available electronically at https://www.regulations.gov as these
references are copyright protected. Some may be available at the
website address, if listed. FDA has verified the website addresses, as
of the date this document publishes in the Federal Register, but
websites are subject to change over time.

1. Aikin, K.J., K.R. Betts, A. Keisler, and K.S. Ziemer, ``Market
Claims and Efficacy Information in Direct-to-Consumer Prescription
Drug Print Advertisements,'' Psychology & Marketing, 36(8), 747-757,
2019a.
2. Aikin, K.J., K.R. Betts, K.S. Ziemer, and A. Keisler, ``Consumer
Tradeoff of Advertising Claim Versus Efficacy Information in Direct-
to-Consumer Prescription Drug Ads,'' Research in Social and
Administrative Pharmacy, 15(12), 1484-1488, 2019b.
3. Arroyo, R., A.P. Sempere, E. Ruiz-Beato, D. Prefasi, et al.
``Conjoint Analysis To Understand Preferences of Patients With
Multiple Sclerosis for Disease-Modifying Therapy Attributes in
Spain: A Cross-Sectional Observational Study,'' BMJ Open, 7(3),
e014433, 2017.
4. Fraenkel, L., L. Suter, C.E. Cunningham, and G. Hawker,
``Understanding Preferences for Disease-Modifying Drugs in
Osteoarthritis,'' Arthritis Care Research, 66(8), 1186-1192, 2014.
5. Wouters, H., G.A. Maatman, L. Van Dijk, M.L. Bouvy, et al.
``Trade-Off Preferences Regarding Adjuvant Endocrine Therapy Among
Women With Estrogen Receptor-Positive Breast Cancer,'' Annals of
Oncology, 24(9), 2324-2329, 2013.
6. Betts, K.R., V. Boudewyns, K.J. Aikin, C. Squire, et al.
``Serious and Actionable Risks, Plus Disclosure: Investigating an
Alternative Approach for Presenting Risk Information in Prescription
Drug Television Advertisements,'' Research in Social and
Administrative Pharmacy, 14(10), 951-963, 2018.

    Dated: October 6, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-22586 Filed 10-11-23; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register: May 19, 2010 (Volume 75, Number 96)]
[Proposed Rules]
[Page 27956-27959]
[DOCID:fr19my10-12]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2010-0478; Directorate Identifier 2008-NM-090-AD]
RIN 2120-AA64

Airworthiness Directives; Airbus Model A300 B4-600, B4-600R, and
F4-600R Series Airplanes, and Model C4-605R Variant F Airplanes
(Collectively Called A300-600 Series Airplanes); and Model A300 and
A310 Series Airplanes

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of proposed rulemaking (NPRM).

-----------------------------------------------------------------------

SUMMARY: We propose to adopt a new airworthiness directive (AD) for the
products listed above. This proposed AD results from mandatory
continuing airworthiness information (MCAI) originated by an aviation
authority of another country to identify and correct an unsafe
condition on an aviation product. The MCAI describes the unsafe
condition as: Two cases of complete nose landing gear (NLG) shock
absorber bolts failure were reported to the manufacturer. In both
cases, the crew was unable to retract the gear and was forced to an In
Flight Turn Back. In one case, the aircraft experienced a low speed
runway excursion. The root cause of the bolts failure has been
identified

being due to a bolt(s) over-torque. The investigation has highlighted
that the design of the NLG shock absorber was not tolerant to the over-
torque, and an inspection plan has been developed to track any NLG
shock absorber-to-main barrel attachment bolts status. The proposed AD
would require actions that are intended to address the unsafe condition
described in the MCAI.

DATES: We must receive comments on this proposed AD by July 6, 2010.

ADDRESSES: You may send comments by any of the following methods:
     Federal eRulemaking Portal: Go to http://
www.regulations.gov. Follow the instructions for submitting comments.
     Fax:<PHONE_NUMBER>.
     Mail: U.S. Department of Transportation, Docket
Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue, SE., Washington, DC 20590.
     Hand Delivery: U.S. Department of Transportation, Docket
Operations, M-30, West Building Ground Floor, Room W12-40, 1200 New
Jersey Avenue, SE., Washington, DC, between 9 a.m. and 5 p.m., Monday
through Friday, except Federal holidays.
    For service information identified in this proposed AD, contact
Airbus SAS--EAW (Airworthiness Office), 1 Rond Point Maurice Bellonte,
31707 Blagnac Cedex, France; telephone +33 5 61 93 36 96; fax +33 5 61
93 44 51; e-mail<EMAIL_ADDRESS>Internet http://
www.airbus.com. You may review copies of the referenced service
information at the FAA, Transport Airplane Directorate, 1601 Lind
Avenue, SW., Renton, Washington. For information on the availability of
this material at the FAA, call<PHONE_NUMBER>.

Examining the AD Docket

    You may examine the AD docket on the Internet at http://
www.regulations.gov; or in person at the Docket Operations office
between 9 a.m. and 5 p.m., Monday through Friday, except Federal
holidays. The AD docket contains this proposed AD, the regulatory
evaluation, any comments received, and other information. The street
address for the Docket Operations office (telephone<PHONE_NUMBER>) is
in the ADDRESSES section. Comments will be available in the AD docket
shortly after receipt.

FOR FURTHER INFORMATION CONTACT: Dan Rodina, Aerospace Engineer,
International Branch, ANM-116, Transport Airplane Directorate, FAA,
1601 Lind Avenue, SW., Renton, Washington 98057-3356; telephone (425)
227-2125; fax<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

Comments Invited

    We invite you to send any written relevant data, views, or
arguments about this proposed AD. Send your comments to an address
listed under the ADDRESSES section. Include ``Docket No. FAA-2010-0478;
Directorate Identifier 2008-NM-090-AD'' at the beginning of your
comments. We specifically invite comments on the overall regulatory,
economic, environmental, and energy aspects of this proposed AD. We
will consider all comments received by the closing date and may amend
this proposed AD based on those comments.
    We have lengthened the 30-day comment period for proposed ADs that
address MCAI originated by aviation authorities of other countries to
provide adequate time for interested parties to submit comments. The
comment period for these proposed ADs is now typically 45 days, which
is consistent with the comment period for domestic transport ADs.
    We will post all comments we receive, without change, to http://
www.regulations.gov, including any personal information you provide. We
will also post a report summarizing each substantive verbal contact we
receive about this proposed AD.

Discussion

    The European Aviation Safety Agency (EASA), which is the Technical
Agent for the Member States of the European Community, has issued EASA
Airworthiness Directive 2008-0052R1, dated June 30, 2008 (referred to
after this as ``the MCAI''), to correct an unsafe condition for the
specified products. The MCAI states:

    Two cases of complete nose landing gear (NLG) shock absorber
bolts failure were reported to the manufacturer. In both cases, the
crew was unable to retract the gear and was forced to an In Flight
Turn Back. In one case, the aircraft experienced a low speed runway
excursion. The root cause of the bolts failure has been identified
being due to a bolt(s) over-torque. The investigation has
highlighted that the design of the NLG shock absorber was not
tolerant to the over-torque, and an inspection plan has been
developed to track any NLG shock absorber-to-main barrel attachment
bolts status. The preliminary inspection plan, required by DGAC
France Airworthiness Directive (AD) F-2004-075 and F-2004-076, has
allowed limiting the number of findings: High at the initial
inspection, it has decreased following the repetitive inspections.
    This new AD retains the requirements of those ADs, which are
superseded, and requires a repetitive torque check of the NLG shock
absorber-to-main barrel attachment bolts with new thresholds and
intervals. This new AD also refers to an optional modification as
terminating action.
* * * * *

The optional modification involves modifying the shock absorber-to-
barrel attachment to increase over-torque tolerances. The actions to
address the unsafe condition also include inspecting the NLG shock
absorber-to-main barrel attachment bolts and doing corrective actions.
The corrective actions include replacing bolts, screws, nuts, washers,
and cotter pins; contacting Airbus for repair and doing the repair; and
modifying the shock absorber; as applicable. The inspection of the NLG
shock absorber-to-main barrel attachment bolts is repeated at intervals
not to exceed 400 flight hours or 1,000 flight cycles, depending on the
inspection results and corrective actions performed. You may obtain
further information by examining the MCAI in the AD docket.

Relevant Service Information

    Airbus has issued the following service information:
     All Operator Telexes A300-32A0447, A300-32A6093, and A310-
32A2132, all dated April 22, 2004;
     Mandatory Service Bulletins A300-32-0447, A300-32-6093,
and A310-32-2132, all Revision 01, all including Appendix 01, all dated
June 1, 2007; and
     Service Bulletins A300-32-0453, A300-32-6099, and A310-32-
2135, all dated June 1, 2007.
    The actions described in this service information are intended to
correct the unsafe condition identified in the MCAI.

FAA's Determination and Requirements of This Proposed AD

    This product has been approved by the aviation authority of another
country, and is approved for operation in the United States. Pursuant
to our bilateral agreement with the State of Design Authority, we have
been notified of the unsafe condition described in the MCAI and service
information referenced above. We are proposing this AD because we
evaluated all pertinent information and determined an unsafe condition
exists and is likely to exist or develop on other products of the same
type design.

Differences Between This AD and the MCAI or Service Information

    We have reviewed the MCAI and related service information and, in
general, agree with their substance. But we might have found it
necessary to use different words from those in the MCAI to ensure the
AD is clear for U.S.

operators and is enforceable. In making these changes, we do not intend
to differ substantively from the information provided in the MCAI and
related service information.
    We might also have proposed different actions in this AD from those
in the MCAI in order to follow FAA policies. Any such differences are
highlighted in a NOTE within the proposed AD.

Costs of Compliance

    Based on the service information, we estimate that this proposed AD
would affect about 229 products of U.S. registry. We also estimate that
it would take about 2 work-hours per product to comply with the basic
requirements of this proposed AD. The average labor rate is $85 per
work-hour. Based on these figures, we estimate the cost of the proposed
AD on U.S. operators to be $38,930, or $170 per product.

Authority for This Rulemaking

    Title 49 of the United States Code specifies the FAA's authority to
issue rules on aviation safety. Subtitle I, section 106, describes the
authority of the FAA Administrator. ``Subtitle VII: Aviation
Programs,'' describes in more detail the scope of the Agency's
authority.
    We are issuing this rulemaking under the authority described in
``Subtitle VII, Part A, Subpart III, Section 44701: General
requirements.'' Under that section, Congress charges the FAA with
promoting safe flight of civil aircraft in air commerce by prescribing
regulations for practices, methods, and procedures the Administrator
finds necessary for safety in air commerce. This regulation is within
the scope of that authority because it addresses an unsafe condition
that is likely to exist or develop on products identified in this
rulemaking action.

Regulatory Findings

    We determined that this proposed AD would not have federalism
implications under Executive Order 13132. This proposed AD would not
have a substantial direct effect on the States, on the relationship
between the national Government and the States, or on the distribution
of power and responsibilities among the various levels of government.
    For the reasons discussed above, I certify this proposed
regulation:
    1. Is not a ``significant regulatory action'' under Executive Order
12866;
    2. Is not a ``significant rule'' under the DOT Regulatory Policies
and Procedures (44 FR 11034, February 26, 1979); and
    3. Will not have a significant economic impact, positive or
negative, on a substantial number of small entities under the criteria
of the Regulatory Flexibility Act.
    We prepared a regulatory evaluation of the estimated costs to
comply with this proposed AD and placed it in the AD docket.

List of Subjects in 14 CFR Part 39

    Air transportation, Aircraft, Aviation safety, Incorporation by
reference, Safety.

The Proposed Amendment

    Accordingly, under the authority delegated to me by the
Administrator, the FAA proposes to amend 14 CFR part 39 as follows:

PART 39--AIRWORTHINESS DIRECTIVES

    1. The authority citation for part 39 continues to read as follows:

    Authority: 49 U.S.C. 106(g), 40113, 44701.

Sec.  39.13  [Amended]

    2. The FAA amends Sec.  39.13 by adding the following new AD:

Airbus: Docket No. FAA-2010-0478; Directorate Identifier 2008-NM-
090-AD.

Comments Due Date

    (a) We must receive comments by July 6, 2010.

Affected ADs

    (b) None.

Applicability

    (c) This AD applies to Airbus Model A300 B2-1A, B2-1C, B4-2C,
B2K-3C, B4-103, B2-203, and B4-203 airplanes; Model A300 B4-601, B4-
603, B4-620, B4-622, B4-605R, B4-622R, F4-605R, F4-622R, and C4-605R
Variant F airplanes; and Model A310-203, -204, -221, -222, -304, -
322, -324, and -325 airplanes; all certified models, all serial
numbers, certificated in any category; except airplanes on which
Airbus Modification 13212 has been done in production or Airbus
Service Bulletin A300-32-0453, A310-32-2135, or A300-32-6099 has
been done in service.

Subject

    (d) Air Transport Association (ATA) of America Code 32: Landing
gear.

Reason

    (e) The mandatory continuing airworthiness information (MCAI)
states:
    Two cases of complete nose landing gear (NLG) shock absorber
bolts failure were reported to the manufacturer. In both cases, the
crew was unable to retract the gear and was forced to an In Flight
Turn Back. In one case, the aircraft experienced a low speed runway
excursion. The root cause of the bolts failure has been identified
being due to a bolt(s) over-torque. The investigation has
highlighted that the design of the NLG shock absorber was not
tolerant to the over-torque, and an inspection plan has been
developed to track any NLG shock absorber-to-main barrel attachment
bolts status. The preliminary inspection plan, required by DGAC
France Airworthiness Directive (AD) F-2004-075 and F-2004-076, has
allowed limiting the number of findings: high at the initial
inspection, it has decreased following the repetitive inspections.
    This new AD retains the requirements of those ADs, which are
superseded, and requires a repetitive torque check of the NLG shock
absorber-to-main barrel attachment bolts with new thresholds and
intervals. This new AD also refers to an optional modification as
terminating action.

The optional modification involves modifying the shock absorber-to-
barrel attachment to increase over-torque tolerances. The actions to
address the unsafe condition also include inspecting the NLG shock
absorber-to-main barrel attachment bolts and corrective actions. The
corrective actions include replacing bolts, screws, nuts, washers,
and cotter pins; contacting Airbus for repair and doing the repair;
and modifying the shock absorber; as applicable.

Compliance

    (f) You are responsible for having the actions required by this
AD performed within the compliance times specified, unless the
actions have already been done.

Inspection and Corrective Action

    (g) At the applicable time specified in paragraph (g)(1),
(g)(2), or (g)(3) of this AD: Do a visual inspection to detect
operational condition (i.e., free of corrosion and not deformed) and
inspect rotation/torque of the NLG shock absorber-to-main barrel
attachment bolts and do all applicable corrective actions, in
accordance with the applicable all operators telex (AOT) identified
in Table 1 of this AD. Do all applicable corrective actions before
further flight. Thereafter, repeat the inspection at the applicable
intervals, depending on inspection results and the corrective
actions performed, as specified in the applicable AOT identified in
Table 1 of this AD.
    (1) For airplanes on which the NLG has been overhauled (the
bolts have been removed) as of the effective date of this AD: Within
30 days or 1,000 flight cycles on the NLG after the effective date
of this AD, whichever occurs later.
    (2) For airplanes on which, as of the effective date of this AD,
the NLG has accumulated less than 1,000 total flight cycles, has not
been overhauled (the bolts have never been removed), since
manufacture of the NLG: Before the accumulation of 1,000 total
flight cycles on the NLG, or within 30 days after the effective date
of this AD, whichever occurs later.
    (3) For airplanes on which, as of the effective date of this AD,
the NLG has accumulated 1,000 or more total flight cycles, and has
not been overhauled since new (the bolts have never been removed):
Within 30 days after the effective date of this AD.

                  Table 1--Airbus All Operator Telexes
------------------------------------------------------------------------
      Airbus all operator telex--                    Dated--
------------------------------------------------------------------------
A300-32A0447...........................  April 22, 2004.
A300-32A6093...........................  April 22, 2004.
A310-32A2132...........................  April 22, 2004.
------------------------------------------------------------------------

Torque Load Inspection and Corrective Action

    (h) At the latest of the compliance times specified in
paragraphs (h)(1), (h)(2), and (h)(3) of this AD, do an inspection
of the torque load of the nuts of the NLG shock absorber-to-main
barrel attachment bolts in accordance with the Accomplishment
Instructions of the applicable service bulletin listed in Table 2 of
this AD. Depending on the torque load value found during the
inspection, before further flight: Retighten the bolt(s) or replace
the discrepant bolt(s), or replace all bolts, in accordance with the
applicable service bulletin listed in Table 2 of this AD.
Thereafter, repeat the torque load inspection at intervals not to
exceed 3,200 flight cycles or 30 months' time-in-service accumulated
by the NLG, whichever occurs first.
    (1) Within 3,200 flight cycles or 30 months since NLG's first
flight, whichever occurs first.
    (2) Within 3,200 flight cycles or 30 months accumulated by the
NLG since installation of new bolts, whichever occurs first.
    (3) Within 3,200 flight cycles or 30 months after the effective
date of this AD, whichever occurs first.

              Table 2--Service Information for Inspections
------------------------------------------------------------------------
    Airbus Mandatory Service        Revision
           Bulletin--                level--             Dated--
------------------------------------------------------------------------
A300-32-0447, including                      01  June 1, 2007.
 Appendix 01.
A300-32-6093, including                      01  June 1, 2007.
 Appendix 01.
A310-32-2132, including                      01  June 1, 2007.
 Appendix 01.
------------------------------------------------------------------------

    (i) After accomplishment of the initial inspection in accordance
with paragraph (h) of this AD, as applicable, the repetitive
inspections of paragraph (g) of this AD are no longer required.

Optional Terminating Action

    (j) For airplanes on which the modification of the shock
absorber-to-barrel attachment has been done in accordance with the
applicable service bulletin listed in Table 3 of this AD, the
requirements of this AD are no longer required, as long as that
modification remains installed.

      Table 3--Service Information for Optional Terminating Action
------------------------------------------------------------------------
       Airbus Service Bulletin--                     Dated--
------------------------------------------------------------------------
A300-32-0453...........................  June 1, 2007.
A300-32-6099...........................  June 1, 2007.
A310-32-2135...........................  June 1, 2007.
------------------------------------------------------------------------

Reporting Requirement

    (k) For each inspection required in paragraph (h) of this AD
that results in re-torque or replacement of bolt(s): At the
applicable time specified in paragraph (k)(1) or (k)(2) of this AD,
send a report to Airbus, using Appendix 01 of the applicable service
bulletin listed in Table 2 of this AD.
    (1) If the inspection was done on or after the effective date of
this AD: Submit the report within 30 days after the inspection.
    (2) If the inspection was done before the effective date of this
AD: Submit the report within 30 days after the effective date of
this AD.

FAA AD Differences

    Note 1: This AD differs from the MCAI and/or service information
as follows: No Differences.

Other FAA AD Provisions

    (l) The following provisions also apply to this AD:
    (1) Alternative Methods of Compliance (AMOCs): The Manager,
International Branch, ANM-116, Transport Airplane Directorate, FAA,
has the authority to approve AMOCs for this AD, if requested using
the procedures found in 14 CFR 39.19. Send information to ATTN: Dan
Rodina, Aerospace Engineer, International Branch, ANM-116, Transport
Airplane Directorate, FAA, 1601 Lind Avenue, SW., Renton, Washington
98057-3356; telephone<PHONE_NUMBER>; fax<PHONE_NUMBER>. Before
using any approved AMOC on any airplane to which the AMOC applies,
notify your principal maintenance inspector (PMI) or principal
avionics inspector (PAI), as appropriate, or lacking a principal
inspector, your local Flight Standards District Office. The AMOC
approval letter must specifically reference this AD.
    (2) Airworthy Product: For any requirement in this AD to obtain
corrective actions from a manufacturer or other source, use these
actions if they are FAA-approved. Corrective actions are considered
FAA-approved if they are approved by the State of Design Authority
(or their delegated agent). You are required to assure the product
is airworthy before it is returned to service.
    (3) Reporting Requirements: For any reporting requirement in
this AD, under the provisions of the Paperwork Reduction Act (44
U.S.C. 3501 et seq.), the Office of Management and Budget (OMB) has
approved the information collection requirements and has assigned
OMB Control Number 2120-0056.

Related Information

    (m) Refer to MCAI European Aviation Safety Agency (EASA)
Airworthiness Directive 2008-0052R1, dated June 30, 2008; and the
service information identified in Tables 1, 2, and 3 of this AD; for
related information.

    Issued in Renton, Washington, on May 3, 2010.
Ali Bahrami,
Manager, Transport Airplane Directorate, Aircraft Certification
Service.
[FR Doc. 2010-11902 Filed 5-18-10; 8:45 am]
BILLING CODE 4910-13-P


---------------------------------------------------------------------------

    Based on the Commission's analysis of the existing information
relating to persons who are subject to the final rule, it is unlikely
that any broker-dealer, clearing agency, investment company, or bank
categorized as a ``small business'' or ``small organization'' under
Rule 0-10 would serve as a covered person, reporting agent, or RNSA, as
they would almost certainly have insufficient capital to participate in
lending activities involving a covered securities loan or would
register with the Commission as a national securities association.
Accordingly, the Commission believes it is unlikely that, in the
future, a substantial number of small entities may become impacted by
the final rule. This is because broker-dealers who have a reporting
obligation or elect to serve as a reporting agent are likely to have at
least $500,000 in total capital; as described above, investment
companies, together with other investment companies in the same group
of related investment companies, who have a reporting obligation are
likely to have net assets of over $50 million as of the end of its most
recent fiscal year; banks who have a reporting obligation are likely to
have total assets of over $5 million; \1211\ clearing agencies who
elect to serve as reporting agents are likely to have compared,
cleared, and settled at least $500 million in securities transactions
during the preceding fiscal year and have had a least $200 million of
funds and securities in its custody or control at all times during the
preceding fiscal year (or at any time that it has been in business, if
shorter); \1212\ or such persons are likely to be affiliated with a
person who is not a small business or small organization as defined
under Rule 0-10.
---------------------------------------------------------------------------

    \1211\ 17 CFR 242.0-10(a).
    \1212\ See 17 CFR 240.0-10(d).
---------------------------------------------------------------------------

    For the foregoing reason, the Commission certifies, pursuant to
section 605(b) of Title 5 of the U.S. Code, that final Rule 10c-1a will
not have a significant economic impact on a substantial number of small
entities.

XII. Other Matters

    If any of the provisions of the final rule, or application thereof
to any person or circumstances, is held to be invalid, such invalidity
shall not affect other provisions or application of such provisions to
other persons or circumstances that can be given effect without the
invalid provision or application.
    Pursuant to the Congressional Review Act,\1213\ the Office of
Information and Regulatory Affairs has designated these rules as a
``major rule,'' as defined by 5 U.S.C. 804(2).
---------------------------------------------------------------------------

    \1213\ 5 U.S.C. 801 et seq.
---------------------------------------------------------------------------

Statutory Authority

    The Commission is adopting final Rule 10c-1a pursuant to Sections
3, 10(b), 10(c), 15(c), 15(h), 15A, 17(a), 23(a) of the Securities
Exchange Act of 1934, 15 U.S.C. 78c, 78j(b), 78j(c), 78k-1, 78o(c),
78o(g), 78o-3, 78q(a), and 78w(a), and Public Law 111-203, 984(b), 124
Stat. 1376 (2010).

List of Subjects in 17 CFR Part 240

    Administrative practice and procedure, Reporting and recordkeeping
requirements, Securities.

Text of Rule Amendments

    For the reasons set out in the preamble, the Commission is amending
title 17, chapter II of the Code of Federal Regulations as follows:

PART 240--GENERAL RULES AND REGULATIONS, SECURITIES EXCHANGE ACT OF
1934

0
1. The general authority citation for part 240 continues to read as
follows:

    Authority:  15 U.S.C. 77c, 77d, 77g, 77j, 77s, 77z-2, 77z-3,
77eee, 77ggg, 77nnn, 77sss, 77ttt, 78c, 78c-3, 78c-5, 78d, 78e, 78f,
78g, 78i, 78j, 78j-1, 78j-4, 78k, 78k-1, 78l, 78m, 78n, 78n-1, 78o,
78o-4, 78o-10, 78p, 78q, 78q-1, 78s, 78u-5, 78w, 78x, 78dd, 78ll,
78mm, 80a-20, 80a-23, 80a-29, 80a-37, 80b-3, 80b-4, 80b-11, and 7201
et seq., and 8302; 7 U.S.C. 2(c)(2)(E); 12 U.S.C. 5221(e)(3); 18
U.S.C. 1350; Pub. L. 111-203, Sec. 939A, 124 Stat. 1376 (2010); and
Pub. L. 112-106, Sec. 503 and 602, 126 Stat. 326 (2012), unless
otherwise noted.
* * * * *
    Section 240.10c-1a also issued under 15 U.S.C. 78j(c), and Pub,
L. 111-203, 984(b), 124 Stat. 1376 (2010).
* * * * *

0
2. Add Sec.  240.10c-1a immediately following Sec.  240.10b-21 to read
as follows:

Sec.  240.10c-1a   Securities lending transparency.

    (a) Reporting requirements for covered persons. Any covered person
who agrees to a covered securities loan on behalf of itself or another
person shall:
    (1) Provide to a registered national securities association
(``RNSA'') the information in paragraphs (c) through (e) of this
section (``Rule 10c-1a information''), in the format and manner
required by the applicable rule(s) of such RNSA, and within the time
periods

specified in paragraphs (c) through (e) of this section.
    (2) Provided, however, a covered person may rely on a reporting
agent to fulfill its reporting obligations under paragraph (a)(1) of
this section if such covered person:
    (i) Enters into a written agreement with a reporting agent that
agrees to provide the Rule 10c-1a information to an RNSA on behalf of
such covered person in accordance with the requirements in paragraph
(b) of this section; and,
    (ii) Provides such reporting agent with timely access to the Rule
10c-1a information.
    (b) Reporting agent requirements. Any reporting agent that assumes
the reporting obligation on behalf of a covered person pursuant to
paragraph (a)(2) of this section shall:
    (1) Provide such Rule 10c-1a information to an RNSA, in the format
and manner required by the applicable rule(s) of such RNSA, and within
the time periods specified in paragraphs (c) through (e) of this
section;
    (2) Establish, maintain, and enforce written policies and
procedures that are reasonably designed to provide Rule 10c-1a
information to an RNSA on behalf of a covered person in the format and
manner required by the applicable rule(s) of an RNSA, and within the
time periods specified in paragraphs (c) through (e) of this section;
    (3) Enter into a written agreement with an RNSA that permits the
reporting agent to provide Rule 10c-1a information to an RNSA on behalf
of a covered person;
    (4) Provide an RNSA with a list naming each covered person on whose
behalf the reporting agent is providing Rule 10c-1a information to an
RNSA and provide an RNSA with any updates to the list of such persons
by the end of the day such list changes; and
    (5) Preserve for a period of not less than three years, the first
two years in an easily accessible place:
    (i) The Rule 10c-1a information obtained by the reporting agent
from the covered person pursuant to paragraph (a)(2) of this section,
including the time of receipt, and the corresponding Rule 10c-1a
information provided by the reporting agent to an RNSA, including the
time of transmission to an RNSA; and
    (ii) The written agreements under paragraphs (a)(2) and (b)(3) of
this section.
    (c) Data elements. A covered person shall provide the following
information, if applicable, to an RNSA, by the end of the day on which
a covered securities loan is effected:
    (1) The legal name of the security issuer, and the Legal Entity
Identifier (``LEI'') of the issuer, if the issuer has a non-lapsed LEI;
    (2) The ticker symbol, International Securities Identification
Number (``ISIN''), Committee on Uniform Securities Identification
Procedures (``CUSIP''), or Financial Instrument Global Identifier
(``FIGI'') of the security, or other security identifier;
    (3) The date the covered securities loan was effected;
    (4) The time the covered securities loan was effected;
    (5) The name of the platform or venue where the covered securities
loan was effected;
    (6) The amount, such as size, volume, or both, of the reportable
securities loaned;
    (7) The type of collateral used to secure the covered securities
loan;
    (8) For a covered securities loan collateralized by cash, the
rebate rate or any other fee or charges;
    (9) For a covered securities loan not collateralized by cash, the
securities lending fee or rate, or any other fee or charges;
    (10) The percentage of collateral to value of reportable securities
loaned required to secure such covered securities loan;
    (11) The termination date of the covered securities loan; and
    (12) Whether the borrower is a broker or dealer, a customer (if the
person lending securities is a broker or dealer), a clearing agency, a
bank, a custodian, or other person.
    (d) Loan modification data elements. A covered person shall provide
the following information to an RNSA by the end of the day on which a
covered securities loan is modified:
    (1) If the modification occurs after the data elements under
paragraph (c) of this section for such covered securities loan are
provided to an RNSA, and results in a change to information previously
required to be provided to an RNSA under paragraph (c) of this section:
    (i) The date and time of the modification;
    (ii) The specific modification and the specific data element in
paragraph (c) of this section being modified; and
    (iii) The unique identifier assigned to the original covered
securities loan under paragraph (g)(1) or (g)(3) of this section;
    (2) If the modification is to a covered securities loan for which
reporting under paragraph (a) was not required on the date the loan was
agreed to or last modified and results in a change to any of the data
elements in paragraphs (c)(1) through (12) of this section:
    (i) The data elements in paragraphs (c)(1) through (12) of this
section as of the date of modification and the date and time of the
modification.
    (ii) [Reserved]
    (e) Confidential data elements. A covered person shall provide the
following information to an RNSA, if applicable, by the end of the day
on which a covered securities loan is effected:
    (1) If known, the legal name of each party to the covered
securities loan, other than the customer from whom a broker or dealer
borrows fully paid or excess margin securities pursuant to Sec.
240.15c3-3(b)(3) (``Rule 15c3-3(b)(3)'') of the Exchange Act, Central
Registration Depository (``CRD'') or Investment Adviser Registration
Depository (``IARD'') Number, market participant identification
(``MPID''), and the LEI of each party to the covered securities loan,
and whether such person is the lender, the borrower, or an intermediary
between the lender and the borrower;
    (2) If the person lending securities is a broker or dealer and the
borrower is its customer, whether the security is loaned from a
broker's or dealer's securities inventory to a customer of such broker
or dealer; and
    (3) If known, whether the covered securities loan is being used to
close out a fail to deliver pursuant to Sec.  242.204 of this chapter
(``Rule 204 of Regulation SHO'') or to close out a fail to deliver
outside of Sec. Sec.  242.200 through 242.204 of this chapter
(``Regulation SHO'').
    (f) RNSA rules. An RNSA shall implement rules regarding the format
and manner of its collection of information described in paragraphs (c)
through (e) of this section and make publicly available such
information in accordance with rules promulgated pursuant to 15 U.S.C.
78s(b) (``section 19(b)'') and Sec.  240.19b-4 (``Rule 19b-4'') of the
Exchange Act.
    (g) RNSA publication of data. An RNSA shall:
    (1) Following receipt of information pursuant to paragraph (c) of
this section, as soon as practicable, and not later than the morning of
the business day after the covered securities loan is effected, assign
a unique identifier to the covered securities loan and make publicly
available the following information:
    (i) For each covered securities loan effected on the previous
business day:
    (A) The unique identifier assigned by an RNSA;
    (B) The information it receives under paragraphs (c)(1) through (5)
and (7) through (12) of this section; and
    (C) The security identifier(s) under paragraphs (c)(1) or (2) of
this section

that an RNSA determines is appropriate to identify the relevant
reportable security.
    (2) Following receipt of information pursuant to paragraph (c) of
this section, on the twentieth business day after the covered
securities loan is effected, make publicly available the information
specified in paragraph (c)(6) of this section along with the loan and
security identifying information specified in paragraphs (g)(1)(i)(A)
and (C) of this section.
    (3) Following receipt of information pursuant to paragraph (d) of
this section, assign a unique identifier to the covered securities loan
if one was not assigned pursuant to paragraph (g)(1)(i)(A) of this
section; and:
    (i) As soon as practicable, and not later than the morning of the
business day after the covered securities loan is modified, make
publicly available information pertaining to any modification to the
data specified in paragraphs (c)(1) through (5) and (7) through (12) of
this section; provided however, for a covered securities loan for which
paragraph (c) information is reported to an RNSA pursuant to paragraph
(d)(2) of this section, make publicly available the data specified in
paragraphs (c)(1) through (5) and (7) through (12); and
    (ii) On the twentieth business day after the covered securities
loan is modified, make publicly available the data specified in
paragraph (c)(6) of this section along with the loan and security
identifying information specified in paragraphs (g)(1)(i)(A) or (g)(3),
as applicable, and (g)(1)(i)(C) of this section.
    (4) Following receipt of information pursuant to paragraph (e) of
this section, keep such information confidential, in accordance with
the provisions of paragraph (h) of this section and applicable law.
    (5) Following the receipt of information specified in paragraphs
(c) and (d) of this section, as soon as practicable, and not later than
the morning of the business day after covered securities loans are
effected or modified, make publicly available, on a daily basis,
information pertaining to the aggregate transaction activity and
distribution of loan rates for each reportable security and the
security identifier(s) under paragraphs (c)(1) or (2) of this section
for which an RNSA determines is appropriate to identify.
    (h) Data retention and availability. An RNSA shall:
    (1) Retain the information collected pursuant to paragraphs (c)
through (e) of this section in a convenient and usable standard
electronic data format that is machine readable and text searchable
without any manual intervention for a period of five years;
    (2) Make the information collected pursuant to paragraphs (b)(4)
and (c) through (e) of this section available to the Commission; or
other persons as the Commission may designate by order upon a
demonstrated regulatory need;
    (3) Make the information collected under paragraphs (c) and (d) of
this section available to the public in the same manner such
information is maintained pursuant to paragraph (h)(1) of this section
on an RNSA's website or similar means of electronic distribution,
without use restrictions, for a period of at least five years; and
    (4) Establish, maintain, and enforce reasonably designed written
policies and procedures to maintain the security and confidentiality of
confidential information required by paragraph (e) of this section.
    (i) RNSA fees. An RNSA may establish and collect reasonable fees,
pursuant to rules that are promulgated pursuant to section 19(b) and
Rule 19b-4 of the Exchange Act.
    (j) Definitions. For purposes of this section:
    (1) The term covered person means:
    (i) Any person that agrees to a covered securities loan on behalf
of a lender (``intermediary'') other than a clearing agency when
providing only the functions of a central counterparty pursuant to
Sec.  240.17Ad-22(a)(2) (``Rule 17Ad-22(a)(2)'') of the Exchange Act or
a central securities depository pursuant to Sec.  240.17Ad-22(a)(3)
(``Rule 17Ad-22(a)(3)'') of the Exchange Act; or
    (ii) Any person that agrees to a covered securities loan as a
lender when an intermediary is not used unless paragraph (j)(1)(iii) of
this section applies; or
    (iii) A broker or dealer when borrowing fully paid or excess margin
securities pursuant to Rule 15c3-3(b)(3) of the Exchange Act.
    (2) The term covered securities loan means:
    (i) A transaction in which any person on behalf of itself or one or
more other persons, lends a reportable security to another person.
    (ii) Notwithstanding paragraph (j)(2)(i) of this section, a
position at a clearing agency that results from central counterparty
services pursuant to Rule 17Ad-22(a)(2) of the Exchange Act or central
securities depository services pursuant to Rule 17Ad-22(a)(3) of the
Exchange Act will not be a covered securities loan for purposes of this
rule.
    (iii) Notwithstanding paragraph (j)(2)(i) of this section, the use
of margin securities, as defined in Sec.  240.15c3-3(a)(4) (``Rule
15c3-3(a)(4)'') of the Exchange Act, by a broker or dealer will not be
a covered securities loan for purposes of this rule.
    (A) Provided, however, if a broker or dealer lends such margin
securities to another person, the loan to the other person is a covered
securities loan for purposes of this rule.
    (B) [Reserved]
    (3) The term reportable security means any security or class of an
issuer's securities for which information is reported or required to be
reported to the consolidated audit trail as required by Sec.  242.613
(``Rule 613'') of the Exchange Act and the CAT NMS Plan (``CAT''), the
Financial Industry Regulatory Authority's Trade Reporting and
Compliance Engine (``TRACE''), or the Municipal Securities Rulemaking
Board's Real-Time Transaction Reporting System (``RTRS''), or any
reporting system that replaces one of these systems.
    (4) The term reporting agent means a broker, dealer, or registered
clearing agency that enters into a written agreement with a covered
person under paragraph (a)(2) of this section.
    (5) The term RNSA means an association of brokers and dealers that
is registered as a national securities association pursuant to 15
U.S.C. 78o-3 (``section 15A'') of the Exchange Act.

    By the Commission.

    Dated: October 13, 2023.
J. Matthew DeLesDernier,
Deputy Secretary.
[FR Doc. 2023-23052 Filed 11-2-23; 8:45 am]
BILLING CODE 8011-01-P


[Federal Register Volume 83, Number 71 (Thursday, April 12, 2018)]
[Notices]
[Pages 15834-15835]
[FR Doc No: 2018-07640]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPP-2017-0008; FRL-9975-58]

Pesticide Product Registration; Receipt of Applications for New
Uses

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: EPA has received applications to register new uses for
pesticide products containing currently registered active ingredients.
Pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act
(FIFRA), EPA is hereby providing notice of receipt and opportunity to
comment on these applications.

DATES: Comments must be received on or before May 14, 2018.

ADDRESSES: Submit your comments, identified by the Docket
Identification (ID) Number and the File Symbol of interest as shown in
the body of this document, by one of the following methods:
     Federal eRulemaking Portal: http://www.regulations.gov.
Follow the online instructions for submitting comments. Do not submit
electronically any information you consider to be

Confidential Business Information (CBI) or other information whose
disclosure is restricted by statute.
     Mail: OPP Docket, Environmental Protection Agency Docket
Center (EPA/DC), (28221T), 1200 Pennsylvania Ave. NW, Washington, DC
20460-0001.
     Hand Delivery: To make special arrangements for hand
delivery or delivery of boxed information, please follow the
instructions at http://www.epa.gov/dockets/contacts.html. Additional
instructions on commenting or visiting the docket, along with more
information about dockets generally, is available at http://www.epa.gov/dockets.

FOR FURTHER INFORMATION CONTACT:  Robert McNally, Biopesticides and
Pollution Prevention Division (7511P), main telephone number: (703)
305-7090, email address: [email protected]; Anita Pease,
Antimicrobials Division (7510P), main telephone number:<PHONE_NUMBER>,
email address: [email protected]; or Michael Goodis, Registration
Division (7505P), main telephone number:<PHONE_NUMBER>, email address:
[email protected]. The mailing address for each contact person is:
Office of Pesticide Programs, Environmental Protection Agency, 1200
Pennsylvania Ave. NW, Washington, DC 20460-0001. As part of the mailing
address, include the contact person's name, division, and mail code.
The division to contact is listed at the end of each application
summary.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this action apply to me?

    You may be potentially affected by this action if you are an
agricultural producer, food manufacturer, or pesticide manufacturer.
The following list of North American Industrial Classification System
(NAICS) codes is not intended to be exhaustive, but rather provides a
guide to help readers determine whether this document applies to them.
Potentially affected entities may include:
     Crop production (NAICS code 111).
     Animal production (NAICS code 112).
     Food manufacturing (NAICS code 311).
     Pesticide manufacturing (NAICS code 32532).

B. What should I consider as I prepare my comments for EPA?

    1. Submitting CBI. Do not submit this information to EPA through
regulations.gov or email. Clearly mark the part or all of the
information that you claim to be CBI. For CBI information in a disk or
CD-ROM that you mail to EPA, mark the outside of the disk or CD-ROM as
CBI and then identify electronically within the disk or CD-ROM the
specific information that is claimed as CBI. In addition to one
complete version of the comment that includes information claimed as
CBI, a copy of the comment that does not contain the information
claimed as CBI must be submitted for inclusion in the public docket.
Information so marked will not be disclosed except in accordance with
procedures set forth in 40 CFR part 2.
    2. Tips for preparing your comments. When preparing and submitting
your comments, see the commenting tips at http://www.epa.gov/dockets/comments.html.

II. Registration Applications

    EPA has received applications to register new uses for pesticide
products containing currently registered active ingredients. Pursuant
to the provisions of FIFRA section 3(c)(4) (7 U.S.C. 136a(c)(4)), EPA
is hereby providing notice of receipt and opportunity to comment on
these applications. Notice of receipt of these applications does not
imply a decision by the Agency on these applications.

III. New Uses

    1. File Symbol: 1677-ELI. Docket ID number: EPA-HQ-OPP-2018-0070.
Applicant: Ecolab, Inc., 1 Ecolab Place, St. Paul, MN 55102. Active
ingredient: Dodecylbenzenesulfonic acid at 96%. Product name: BIO-SOFT
S-101 MUP. Product type: Antimicrobial. Proposed use: Manufacturing Use
Antimicrobial product for use in the formulation of sanitizer,
disinfectant, and antimicrobial/biocidal formulations/products.
Contact: AD.
    2. File Symbol: 39967-RUI. Docket ID number: EPA-HQ-OPP-2018-0044.
Applicant: LanXess Corporation, 111 RIDC Park West Drive Pittsburgh, PA
15275-1112. Active ingredient: Penflufen. Product type: Antimicrobial.
Product name: Preventol A800 Technical Fungicide. Proposed use:
Fungicide Used for the Preservation of Wood composite products, wood
products intended for above ground and in-ground contact, wood stains.
Contact: AD.
    3. File Symbol: 39967-RUO. Docket ID number: EPA-HQ-OPP-2018-0044.
Applicant: LanXess Corporation, 111 RIDC Park West Drive, Pittsburgh,
PA 15275-1112. Active ingredient: Penflufen. Product type:
Antimicrobial. Product name: Preventol A800 Preservative. Proposed use:
Fungicide Used for the Preservation of Wood composite products, wood
products intended for above ground and in-ground contact, wood stains.
Contact: AD.
    4. EPA Registration Numbers: 7969-198, 7969-251, 7969-197, 7969-
199. Docket ID number: EPA-HQ-OPP-2017-0310. Applicant: BASF
Corporation, P.O. Box 13528, 26 Davis Drive, Research Triangle Park, NC
27709. Active ingredient: Boscalid. Product type: Fungicide. Proposed
use: Brassica, leafy greens, subgroup 4-16B; celtuce; fennel, Florence;
kohlrabi; leafy petiole vegetable, subgroup 22B; leafy greens, subgroup
4-16A; pea and bean, dried shelled, except soybean, subgroup 6C; Pea
and bean, succulent shelled, subgroup 6B; vegetable, brassica, head and
stem, group 5-16; vegetable, cucurbit, group 9; vegetable, root, except
sugar beet, subgroup 1B; vegetable, fruiting, group 8-10. Contact: RD.
    5. File Symbols: 8329-RRE, 8329-RRN, and 8329-RRR. Docket ID
number: EPA-HQ-OPP-2018-0093. Applicant: Clarke Mosquito Control
Products, Inc., 675 Sidwell Ct., St. Charles, IL 60174. Active
ingredient: l-carvone. Product type: Insecticide. Proposed use: Wide-
area mosquito adulticide. Contact: BPPD.
    6. EPA File Symbol: 92587-R. Docket ID number: EPA-HQ-OPP-2018-
0067. Applicant: QTEK, LLC, 20316 Chassell Painesdale Road, Chassell,
MI 49916. Product name: Surfion[supreg] Additive. Active ingredient:
Cupric Oxide at 3.19%. Product type: Antimicrobial. Proposed use: End
use Antimicrobial Product for use as a bacteriostatic and fungistatic
additive for use in the manufacture and preservation of commodity
products. Contact: AD.

    Authority:  7 U.S.C. 136 et seq.

    Dated: March 20, 2018.
Delores Barber,
Director, Information Technology and Resources Management Division,
Office of Pesticide Programs.
[FR Doc. 2018-07640 Filed 4-11-18; 8:45 am]
 BILLING CODE 6560-50-P


[Federal Register Volume 85, Number 174 (Tuesday, September 8, 2020)]
[Notices]
[Pages 55444-55445]
[FR Doc No: 2020-19768]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP20-514-000]

Transcontinental Gas Pipe Line Company, LLC; Notice of Request
Under Blanket Authorization

    Take notice that on August 24, 2020, Transcontinental Gas Pipe Line
Company, LLC (Transco), Post Office Box 1396, Houston, Texas 77251,
filed a prior notice application pursuant to sections 157.205 and
157.216 of the Federal Energy Regulatory Commission's (Commission)
regulations under the Natural Gas Act, and Transco's blanket
certificate issued in Docket No. CP82-426. Transco proposes to abandon
an existing 6-inch supply lateral interconnecting with Transco's
Mainline A, (hereinafter referred to as the Shell Elba Lateral) and
appurtenant metering facilities, all located in St. Landry Parish,
Louisiana. Details of Transco's project is more fully set forth in the
application which is on file with the Commission and open to public
inspection.
    In addition to publishing the full text of this document in the
Federal Register, the Commission provides all interested persons an
opportunity to view and/or print the contents of this document via the
internet through the Commission's Home Page (http://ferc.gov) using the
``eLibrary'' link. Enter the docket number excluding the last three
digits in the docket number field to access the document. At this time,
the Commission has suspended access to the Commission's Public
Reference Room, due to the proclamation declaring a National Emergency
concerning the Novel Coronavirus Disease (COVID-19), issued by the
President on March 13, 2020. For assistance, contact FERC at
<EMAIL_ADDRESS>or call toll-free,<PHONE_NUMBER> or TYY,
(202) 502-8659.
    Any questions regarding this application should be directed to
Andre Pereira, Regulatory Analyst, Senior, at: P.O. Box 1396, Houston,
Texas 77251; or by phone at:<PHONE_NUMBER>.
    Any person or the Commission's staff may, within 60 days after the
issuance of the instant notice by the Commission, file pursuant to Rule
214 of the Commission's Procedural Rules (18 CFR 385.214) a motion to
intervene or notice of intervention. Any person filing to intervene, or
the Commission's staff may, pursuant to section 157.205 of the
Commission's Regulations under the NGA (18 CFR 157.205) file a protest
to the request. If no protest is filed within the time allowed
therefore, the proposed activity shall be deemed to be authorized
effective the day after the time allowed for protest. If a protest is
filed and not withdrawn within 30 days after the time allowed for
filing a protest, the instant request shall be treated as an
application for authorization pursuant to section 7 of the NGA.
    Pursuant to section 157.9 of the Commission's rules, 18 CFR 157.9,
within 90 days of this Notice the Commission staff will either:
Complete its environmental assessment (EA) and place it into the
Commission's public record (eLibrary) for this proceeding; or issue a
Notice of Schedule for Environmental Review. If a Notice of Schedule
for Environmental Review is issued, it will indicate, among other
milestones, the anticipated date for the Commission staff's issuance of
the EA for this proposal. The filing of the EA in the Commission's
public record for this proceeding or the issuance of a

Notice of Schedule for Environmental Review will serve to notify
federal and state agencies of the timing for the completion of all
necessary reviews, and the subsequent need to complete all federal
authorizations within 90 days of the date of issuance of the Commission
staff's EA.
    Persons who wish to comment only on the environmental review of
this project should submit an original and two copies of their comments
to the Secretary of the Commission. Environmental commenters will be
placed on the Commission's environmental mailing list and will be
notified of any meetings associated with the Commission's environmental
review process. Environmental commenters will not be required to serve
copies of filed documents on all other parties. However, the non-party
commenters will not receive copies of all documents filed by other
parties or issued by the Commission and will not have the right to seek
court review of the Commission's final order.
    The Commission strongly encourages electronic filings of comments
in lieu of paper using the ``eFile'' link at http://www.ferc.gov. In
lieu of electronic filing, you may submit a paper copy. Submissions
sent via the U.S. Postal Service must be addressed to: Kimberly D.
Bose, Secretary, Federal Energy Regulatory Commission, 888 First Street
NE, Room 1A, Washington, DC 20426. Submissions sent via any other
carrier must be addressed to: Kimberly D. Bose, Secretary, Federal
Energy Regulatory Commission, 12225 Wilkins Avenue, Rockville, Maryland
20852.

    Dated: September 1, 2020.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2020-19768 Filed 9-4-20; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 77, Number 103 (Tuesday, May 29, 2012)]
[Notices]
[Pages 31631-31632]
[FR Doc No: 2012-12874]

-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

[Docket No. USCG-2012-0458]

Towing Safety Advisory Committee; Vacancies

AGENCY: Coast Guard, DHS.

ACTION: Request for applications.

-----------------------------------------------------------------------

SUMMARY: The Coast Guard seeks applications for membership on the
Towing Safety Advisory Committee (TSAC). This Committee advises the
Secretary of Homeland Security on matters relating to shallow-draft
inland and coastal waterway navigation and towing safety.

DATES: Applicants should submit a cover letter and resume in time to
reach Patrick Mannion, the Alternate Designated Federal Officer (ADFO)
on or before July 13, 2012.

ADDRESSES: If you wish to apply for membership, your resume should be
submitted by one of the following methods:
     E-mail<EMAIL_ADDRESS>     Fax:<PHONE_NUMBER> ATTN: Mr. Patrick Mannion, TSAC ADFO.
     Mail: Mr. Patrick Mannion, TSAC ADFO, Commandant (CG-
5222), U.S. Coast Guard, 2100 Second St. SW., STOP 7126, Washington, DC
20593-7126.

FOR FURTHER INFORMATION CONTACT: Commander Rob Smith, Designated
Federal Officer (DFO) of the Towing Safety Advisory Committee (TSAC),
202-372-1410<EMAIL_ADDRESS>or Patrick Mannion, Alternate
Designated Federal Officer of Towing Safety Advisory Committee (TSAC);
telephone<PHONE_NUMBER>; fax<PHONE_NUMBER>; or email at
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: The TSAC is a Federal advisory committee
established in accordance with the provisions of the Federal Advisory
Committee Act (FACA) 5 U.S.C. (Pub. L. 92-463) and under the authority
of Title 33, United States Code, section 1231a, as amended by section
621 of the Coast Guard Authorization Act of 2010 (Pub. L. 111-281). The
Committee advises the Secretary of Homeland Security on matters
relating to shallow-draft inland and coastal waterway navigation and
towing safety. See 33 U.S.C. 1321a.
    Normally, the Committee is expected to meet at least twice a year
either in the Washington DC area or in a city with large towing centers
of commerce and populated by high concentrations of towing industry and
related businesses. The Committee may also be called to meet for
extraordinary purposes. Subcommittees and workgroups may conduct
intercessional telephonic meetings when necessary for specific tasking.
    As specified in 33 U.S.C. 1231a, the Committee is to consist of 18
members:
    [cir] Seven members representing the Barge and Towing industry
(reflecting a regional geographical balance);
    [cir] One member representing the offshore mineral and oil supply
vessel industry;
    [cir] One member representing holders of active licensed Masters or
Pilots of towing vessels with experience on the Western Rivers and the
Gulf Intracoastal Waterway.
    [cir] One member representing the holders of active licensed
Masters of towing vessels in offshore service.
    [cir] One member representing Masters who are active ship-docking
or harbor towing vessel.
    [cir] One member representing licensed or unlicensed towing vessel
engineers with formal training and experience.
    [cir] Two members representing each of the following groups:
    [ssquf] Port districts, authorities, or terminal operators;
    [ssquf] Shippers (of whom at least one shall be engaged in the
shipment of oil or hazardous materials by barge);
    [cir] Two members representing the General Public.
    We will consider applicants for five positions that expire or
become vacant on September 30, 2012:
     Two representatives from the Barge and Towing industry;
     One representative from the offshore mineral and oil
supply vessel industry;
     One representative from shippers; and

     One member from the general public.
    To be eligible, applicants should have expertise, knowledge, and
experience relative to the position in the towing industry, marine
transportation, or business operations associated with shallow-draft
inland and coastal waterway navigation and towing safety. If you are
selected as a non-representative member, or as a member who represents
the general public, you will be appointed and serve as a Special
Government Employee (SGE) as defined in section 202(a) of title 18,
United States Code. As a candidate for appointment as a SGE, applicants
are required to complete a Confidential Financial Disclosure Report
(OGE Form 450). Coast Guard may not release the reports or the
information in them to the public except under an order issued by a
Federal court or as otherwise provided under the Privacy Act (5 U.S.C.
552a). Applicants can obtain this form by going to the Web site of the
Office of Government Ethics (www.oge.gov), or by contacting the
individual listed above. Applications which are not accompanied by a
completed OGE Form 450 will not be considered.
    Each member serves for a term of up to 3 years. Members may be
considered to serve consecutive terms. All members serve at their own
expense and receive no salary, or other compensation from the Federal
Government. The exception to this policy is the possible reimbursement
of travel and per diem expenses depending on fiscal budgetary
constraints.
    Registered lobbyists are not eligible to serve on Federal advisory
committees. Registered lobbyists are lobbyists required to comply with
provisions contained in the Lobbying Disclosure Act of 1995 (Pub. L.
104-65, as amended by Title II of Pub. L. 110-81.
    The Department of Homeland Security (DHS) does not discriminate in
employment on the basis of race, color, religion, sex, national origin,
political affiliation, sexual orientation, gender identity, marital
status, disability and genetic information, age, membership in an
employee organization, or other non-merit factor. DHS strives to
achieve a widely diverse candidate pool for all of its recruitment
actions.
    To visit our online docket, go to http://www.regulations.gov, enter
the docket number for this notice (USCG-2012-0458) in the Search box,
and press Enter.'' Please do not post your resume on this site. During
the vetting process, applicants may be asked to provide date of birth
and social security number.

    Dated: May 21, 2012.
F.J. Sturm,
Acting Director of Commercial Regulations and Standards.
[FR Doc. 2012-12874 Filed 5-25-12; 8:45 am]
BILLING CODE 9110-04-P


[Federal Register: July 2, 2008 (Volume 73, Number 128)]
[Rules and Regulations]
[Page 37809]
[DOCID:fr02jy08-15]

-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

33 CFR Part 117

[USCG-2008-0592]

Drawbridge Operation Regulations; Thames River, New London, CT

AGENCY: Coast Guard, DHS.

ACTION: Notice of temporary deviation from regulations.

-----------------------------------------------------------------------

SUMMARY: The Commander, First Coast Guard District, has issued a
temporary deviation from the regulations governing the operation of the
Amtrak Bridge, mile 3.0, across the Thames River at New London,
Connecticut. While this temporary deviation is in effect, the bridge
may remain in the closed position for three days and operate on a
temporary operating schedule for nine days.

DATES: This deviation is effective from June 28, 2008 through July 9,
2008.

ADDRESSES: Documents indicated in this preamble as being available in
the docket are part of docket USCG-2008-0592 and are available online
at http://www.regulations.gov. They are also available for inspection
or copying at two locations: the Docket Management Facility (M-30),
U.S. Department of Transportation, West Building Ground Floor, Room
W12-140, 1200 New Jersey Avenue, SE., Washington, DC 20590, between 9
a.m. and 5 p.m., Monday through Friday, except Federal holidays, and
the First Coast Guard District, Bridge Branch Office, 408 Atlantic
Avenue, Boston, Massachusetts 02110, between 7 a.m. and 3 p.m., Monday
through Friday, except Federal holidays.

FOR FURTHER INFORMATION CONTACT: Judy Leung-Yee, Project Officer, First
Coast Guard District, at<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION: The Amtrak Bridge, across the Thames River
at mile 3.0, at New London, Connecticut, has a vertical clearance in
the closed position of 30 feet at mean high water and 33 feet at mean
low water. The existing drawbridge operation regulations are listed at
33 CFR 117.224.
    The waterway has seasonal recreational vessels, fishing vessels,
and U.S. Navy vessels of various sizes. The U.S. Navy and other marine
facilities were notified regarding this deviation and no objections
were received.
    The owner of the bridge, National Railroad Passenger Corporation
(Amtrak), requested a temporary deviation to facilitate rehabilitation
construction at the bridge.
    Under this temporary deviation the Amtrak Bridge, mile 3.0, across
the Thames River at New London may remain in the closed position from
June 28, 2008 through June 30, 2008.
    From July 1, 2008, through July 9, 2008, the draw may remain in the
closed position; except that, the draw shall open for the passage of
vessel traffic during the following time periods:
    Monday through Thursday from: 5 a.m. to 5:40 a.m.; 11:20 a.m. to
11:55 a.m.; 3:35 p.m. to 4:15 p.m.; and 8:30 p.m. to 8:55 p.m.
    Friday and Saturday from: 8:30 a.m. to 9:10 a.m.; 12:35 p.m. to
1:05 p.m.; 3:40 p.m. to 4:10 p.m.; 5:35 p.m. to 6:05 p.m.; and 7:35
p.m. to 8:40 p.m.
    Sunday from: 8:30 a.m. to 9:20 a.m.; 11:35 a.m. to 12:15 p.m.; 1:30
p.m. to 1:55 p.m.; 6:30 p.m. to 7:10 p.m.; and 8:30 p.m. to 9:15 p.m.
    The draw shall open on signal at any time for U.S. Navy submarines
and their associated escort vessels.
    Vessels that can pass under the bridge without a bridge opening may
do so at all times.
    In accordance with 33 CFR 117.35(e), the bridge must return to its
regular operating schedule immediately at the end of the designated
time period. This deviation from the operating regulations is
authorized under 33 CFR 117.35.

    Dated: June 25, 2008.
Gary Kassof,
Bridge Program Manager, First Coast Guard District.
[FR Doc. E8-15026 Filed 7-1-08; 8:45 am]

BILLING CODE 9110-04-P